{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=cGVHD&page=15",
    "query": {
      "condition": "cGVHD",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 13473,
    "total_pages": 1348,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=cGVHD&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=cGVHD&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T10:47:34.757Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05452317",
      "title": "Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Antibody-mediated Rejection in Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Chronic active AMR group",
          "type": "OTHER"
        },
        {
          "name": "Non-Chronic active AMR group",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2022-07-14",
      "completion_date": "2023-04-04",
      "has_results": false,
      "last_update_posted_date": "2023-04-13",
      "last_synced_at": "2026-10-23T10:47:34.757Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • St Louis, Missouri",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05452317"
    },
    {
      "nct_id": "NCT03795389",
      "title": "Study to Assess PK, Safety and Tolerability in Patients With DM and CKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Chronic Kidney Disease, Stage 3 (Moderate)",
        "Chronic Kidney Disease, Stage 4 (Severe)",
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "DM199",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DiaMedica Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2019-02-12",
      "completion_date": "2019-07-21",
      "has_results": false,
      "last_update_posted_date": "2021-09-13",
      "last_synced_at": "2026-10-23T10:47:34.757Z",
      "location_count": 3,
      "location_summary": "Hialeah, Florida • Orlando, Florida • Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03795389"
    },
    {
      "nct_id": "NCT02169791",
      "title": "Nonmyeloablative Haploidentical Transplant Followed by MLN9708",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia",
        "Chronic Leukemia",
        "Myelodysplastic Syndrome",
        "Lymphomas",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "MLN9708",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northside Hospital, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2014-07-15",
      "completion_date": "2020-07-28",
      "has_results": true,
      "last_update_posted_date": "2021-09-02",
      "last_synced_at": "2026-10-23T10:47:34.757Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02169791"
    },
    {
      "nct_id": "NCT03425266",
      "title": "The Pain App Study: A Novel Shared Decision Making Tool for People With Chronic Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "Interactive decision support tool",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Shared Decision Making Resources",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2018-01-11",
      "completion_date": "2018-10-31",
      "has_results": false,
      "last_update_posted_date": "2023-12-12",
      "last_synced_at": "2026-10-23T10:47:34.757Z",
      "location_count": 1,
      "location_summary": "Georgetown, Maine",
      "locations": [
        {
          "city": "Georgetown",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03425266"
    },
    {
      "nct_id": "NCT01867190",
      "title": "Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Critical Limb Ischemia"
      ],
      "interventions": [
        {
          "name": "ASCT01 (Autologous Stem Cell Transplantation)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Lifecells, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 24,
      "start_date": "2013-05",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2019-02-22",
      "last_synced_at": "2026-10-23T10:47:34.757Z",
      "location_count": 1,
      "location_summary": "North Kansas City, Missouri",
      "locations": [
        {
          "city": "North Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01867190"
    },
    {
      "nct_id": "NCT07016412",
      "title": "Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Ensifentrine 3 mg",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrrolate 21.25 mcg",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrrolate 42.5 mcg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 497,
      "start_date": "2025-07-31",
      "completion_date": "2026-08-17",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-23T10:47:34.757Z",
      "location_count": 57,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07016412"
    },
    {
      "nct_id": "NCT02592330",
      "title": "Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Limbal Stem Cell Deficiency"
      ],
      "interventions": [
        {
          "name": "Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft",
          "type": "PROCEDURE"
        },
        {
          "name": "Cultivation of Limbal epithelial cells into a graft",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CALEC Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 23,
      "start_date": "2016-08-01",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-15",
      "last_synced_at": "2026-10-23T10:47:34.757Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02592330"
    },
    {
      "nct_id": "NCT01652092",
      "title": "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "SCID",
        "Omenn's Syndrome",
        "Reticular Dysgenesis",
        "Wiskott-Aldrich Syndrome",
        "Bare Lymphocyte Syndrome",
        "Common Variable Immunodeficiency",
        "Chronic Granulomatous Disease",
        "CD40 Ligand Deficiency",
        "Hyper IgM Syndrome",
        "X-linked Lymphoproliferative Disease",
        "Hemophagocytic Lymphohistiocytosis",
        "Griscelli Syndrome",
        "Chediak-Higashi Syndrome",
        "Langerhan's Cell Histiocytosis"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab 0.3 mg",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplantation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine phosphate 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab 0.2 mg",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine phosphate 30 mg",
          "type": "DRUG"
        },
        {
          "name": "MESNA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "Up to 50 Years"
      },
      "enrollment_count": 57,
      "start_date": "2012-09-04",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-23T10:47:34.757Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01652092"
    },
    {
      "nct_id": "NCT04379011",
      "title": "Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Spinal Cord Injuries"
      ],
      "interventions": [
        {
          "name": "Brivaracetam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2021-02-01",
      "completion_date": "2024-09-01",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-10-23T10:47:34.757Z",
      "location_count": 2,
      "location_summary": "Englewood, Colorado • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04379011"
    },
    {
      "nct_id": "NCT00103844",
      "title": "Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia",
        "Philadelphia-Positive Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2005-02",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2010-08-10",
      "last_synced_at": "2026-10-23T10:47:34.757Z",
      "location_count": 53,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Bakersfield, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00103844"
    }
  ]
}